Connecting Psychiatry - Expert community for all mental health professionals

Utilization of MRS to Identify Neurochemical Abnormalities in Patients With Bipolar Disorder

(PSYCHIATRIC TIMES) - Magnetic resonance spectroscopy (MRS) is a useful, noninvasive method of examining alterations in brain neurochemistry that might be associated with the development of bipolar disorder (BD) and the effects of treatment (Soares et al., 1996). It uses the same technology as magnetic resonance imaging and provides a frequency signal intensity spectrum of multiple peaks that reflect the metabolite levels of a localized region in the brain. Magnetic resonance spectroscopy data are usually displayed in the frequency domain, and the area under a specific peak is proportional to the number of protons processing at that frequency (Stanley, 2002). It can assess chemicals containing phosphorus-31 (31P), carbon-13 (13C), lithium-7 and fluorine-19. The most commonly used, however, is proton magnetic resonance spectroscopy (1H-MRS).
1H-MRS Studies

N-acetylaspartate (NAA) is the predominant resonance in the 1H-MRS spectrum of the normal adult human brain. It is an amino acid found in high concentrations in mature neurons and considered to be a marker of neuronal integrity and viability. Reductions in NAA may also reflect impairment in the formation and maintenance of myelin and mitochondrial energy production (Baslow, 2002). In adults with BD, decreased NAA levels were reported in the dorsolateral prefrontal cortex (DLPFC) (Winsberg et al., 2000), orbital frontal gray matter (Cecil et al., 2002) and hippocampus (Bertolino et al., 2003; Deicken et al., 2002). Lower DLPFC NAA levels were also reported in children (Chang et al., 2003) and adolescents (Kusumakar et al., 2002) with BD. Investigating treatment-induced effects, the administration of lithium (Eskalith, Lithobid) during a four-week period was shown to increase brain NAA concentration as indirect evidence of its neurotrophic/neuroprotective effects (Moore et al., 2000; Silverstone et al., 2003). This increase has not been demonstrated with divalproex (Depakote) (Silverstone et al., 2003).

Lithium and divalproex were also recently shown to be protective against dextroamphetamine (a human model of mania)-induced choline decrease (Silverstone et al., 2004). The choline (Cho) peak in the 1H-MRS is considered a potential biomarker for the status of membrane phospholipid metabolism, and basal ganglia Cho/creatine (Cr) is elevated in the euthymic (Kato et al., 1996; Sharma et al., 1992) and depressive state (Hamakawa et al., 1998) in patients with BD. Lithium treatment did not appear to alter Cho resonance in the parietal lobes in seven male patients compared to healthy controls (Stoll et al., 1992) or in the temporal cortex of healthy volunteers (Silverstone et al., 1999). In a case series (n=6), Stoll et al. (1996) demonstrated that oral Cho in combination with lithium was an effective therapy for some patients with treatment-refractory rapid-cycling BD.

Glutamate, glutamine and γ-aminobutyric acid (GABA) are also of interest, as antiglutamatergic and GABAergic anticonvulsants appear useful in treating BD. In a majority of MRS reports, the Glx region refers to glutamate and glutamine. In a group of adolescents with bipolar depression, a bilateral increase in Glx in the frontal cortex and basal ganglia has been reported (Castillo et al., 2000). Glutamatergic abnormalities may be involved in neurotoxicity that is potentially responsible for specific brain insults in BD. Decreased GABA levels were reported in the occipital cortex in nonmedicated patients with unipolar depression (Sanacora et al., 1999). Occipital cortex GABA concentrations after selective serotonin reuptake inhibitor (Sanacora et al., 2002) and electroconvulsive therapy treatment (Sanacora et al., 2003) were significantly higher than pretreatment concentrations. Patients with BD appear not to have such reduction in GABA levels (Mason et al., 2000).

Another important metabolite in 1H-MRS is myo-inositol (mI), which is a substrate for the phosphoinositide cycle. At therapeutic levels, lithium inhibits inositol monophosphatase and polyphosphate-1-phosphatase, which are involved in recycling inositol mono- and polyphosphates to mI (Berridge and Irvine, 1989). Divalproex also decreases the concentration of mI and increases the concentration of inositol monophosphate in rat brains (O'Donnell et al., 2003).

Moore et al. (1999) found decreased mI in the right frontal lobe of depressed patients with BD following acute (five to seven days) lithium administration, which persisted through one month of treatment. However, the patients' clinical state was clearly unchanged at this time, supporting the hypothesis that the initial actions of lithium may occur with a reduction of mI and that this reduction initiates a cascade of secondary changes that are ultimately responsible for lithium's therapeutic efficacy. Consistent with this, Davanzo et al. (2001) observed a significant decrease in anterior cingulate mI/Cr ratios following seven days of lithium therapy in children and adolescents with early-onset BD. Children in a manic phase demonstrated elevated mI/Cr levels within the anterior cingulate cortex.

For full article, please visit:

Views: 7


You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds

psychiatryRounds Social Media


CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service